Open access · CC-BY
via OpenAlex
Drug discovery: Insights from the invertebrate Caenorhabditis elegans
Sebastián Giunti, Natalia Andersen, Diego Rayes, Marı́a José De Rosa
Pharmacology Research & Perspectives · 2021 · ▲ 101 citations
Abstract
Therapeutic drug development is a long, expensive, and complex process that usually takes 12-15 years. In the early phases of drug discovery, in particular, there is a growing need for animal models that ensure the reduction in both cost and time. Caenorhabditis elegans has been traditionally used to address fundamental aspects of key biological processes, such as apoptosis, aging, and gene expression regulation. During the last decade, with the advent of large-scale platforms for screenings, this invertebrate has also emerged as an essential tool in the pharmaceutical research industry to identify novel drugs and drug targets. In this review, we discuss the reasons why C. elegans has been positioned as an outstanding cost-effective option for drug discovery, highlighting both the advantages and drawbacks of this model. Particular attention is paid to the suitability of this nematode in large-scale genetic and pharmacological screenings. High-throughput screenings in C. elegans have indeed contributed to the breakthrough of a wide variety of candidate compounds involved in extensive fields including neurodegeneration, pathogen infections and metabolic disorders. The versatility of this nematode, which enables its instrumentation as a model of human diseases, is another attribute also herein underscored. As illustrative examples, we discuss the utility of C. elegans models of both human neurodegenerative diseases and parasitic nematodes in the drug discovery industry. Summing up, this review aims to demonstrate the impact of C. elegans models on the drug discovery pipeline.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1002/prp2.721
- Canonical
- link ↗
- Fetched
- 2026-09-09 MST
Cite this
APA
Giunti, S., Andersen, N., Rayes, D., & Rosa, M.J.D. (2021). Drug discovery: Insights from the invertebrate Caenorhabditis elegans. <em>Pharmacology Research & Perspectives</em>. https://doi.org/10.1002/prp2.721
Vancouver
Giunti S, Andersen N, Rayes D, Rosa MJD. Drug discovery: Insights from the invertebrate Caenorhabditis elegans. Pharmacology Research & Perspectives. 2021. doi:10.1002/prp2.721.
BibTeX
@article{sebastin2021Drugdi,
title = {Drug discovery: Insights from the invertebrate Caenorhabditis elegans},
author = {Sebastián Giunti and Natalia Andersen and Diego Rayes and Marı́a José De Rosa},
journal = {Pharmacology Research & Perspectives},
year = {2021},
doi = {10.1002/prp2.721},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Pharmacological Reviews 2011
Open access · OA
Genome-Environment Interactions That Modulate Aging: Powerful Targets for Drug Discovery
PLoS ONE 2007
Open access · CC-BY
Identification of Potential Therapeutic Drugs for Huntington's Disease using Caenorhabditis elegans
Acta Materia Medica 2023
Open access · CC-BY
Aging and cancer hallmarks as therapeutic targets
Neurochemical Research 2003
Citation only
Age-Related Retinal Degeneration in Animal Models of Aging: Possible Involvement of Taurine Deficiency and Oxidative Stress
Acta Pharmaceutica Sinica B 2025
Open access · CC-BY
Unraveling the meta-hallmarks between senescent and tumor cells: A new perspective for senolytic drug discovery
eLife 2017
Open access · CC-BY